Table 3.
Adjusted Effect of Microsatellite (Msat) Mismatching on Probability of Grades III-IV Acute GVHD and Overall Mortality After Hematopoietic Cell Transplantation from HLA-identical Unrelated Donors*
| Proportion (%) of Events | |||||
|---|---|---|---|---|---|
| Clinical | Msat | Msat | |||
| Endpoint | Msat | Matched | Mismatched | OR or HR (95% CI)† | P |
| Grades III-IV | |||||
| acute GVHD | D6S276 | 48/143 (34) | 204/657 (31) | 0.83 (0.56–1.24) | .37 |
| D6S105 | 64/217 (30) | 188/583 (32) | 1.07 (0.76–1.52) | .69 | |
| D6S510 | 192/600 (32) | 61/204 (30) | 0.92 (0.64–1.33) | .67 | |
| D6S265 | 200/601 (33) | 52/199 (26) | 0.67 (0.45–0.98) | .04 | |
| D6S2811 | 180/544 (33) | 73/259 (28) | 0.76 (0.54–1.07) | .11 | |
| D6S2810 | 171/535 (32) | 59/187 (32) | 0.94 (0.65–1.35) | .74 | |
| D6S2787 | 177/545 (33) | 75/258 (29) | 0.83 (0.59–1.17) | .29 | |
| D6S273 | 153/512 (30) | 97/284 (34) | 1.23 (0.89–1.71) | .21 | |
| D6S2876 | 236/739 (32) | 17/65 (26) | 0.71 (0.39–1.31) | .28 | |
| D6S2874 | 155/496 (31) | 98/308 (32) | 1.00 (0.73–1.38) | .99 | |
| D6S2749 | 72/266 (27) | 181/538 (34) | 1.36 (0.97–1.91) | .08 | |
| D6S291 | 66/203 (33) | 186/593 (31) | 0.99 (0.70–1.40) | .94 | |
| Overall | |||||
| mortality | D6S276 | 40/76 (53) | 458/738 (62) | 1.38 (0.98–1.94) | .07 |
| D6S105 | 79/150 (53) | 417/663 (63) | 1.32 (1.02–1.71) | .03 | |
| D6S510 | 351/576 (61) | 151/242 (62) | 1.00 (0.82–1.47) | .92 | |
| D6S265 | 358/581 (62) | 139/232 (60) | 0.86 (0.70–1.07) | .19 | |
| D6S2811 | 339/537 (63) | 162/280 (58) | 0.80 (0.66–0.98) | .03 | |
| D6S2810 | 336/530 (63) | 113/204 (55) | 0.81 (0.65–1.00) | .06 | |
| D6S2787 | 294/511 (58) | 206/306 (67) | 1.26 (1.03–1.53) | .02 | |
| D6S273 | 272/460 (59) | 225/350 (64) | 1.18 (0.98–1.43) | .08 | |
| D6S2876 | 450/741 (61) | 51/77 (66) | 0.99 (0.72–1.35) | .95 | |
| D6S2874 | 219/366 (60) | 282/452 (62) | 1.17 (0.97–1.41) | .10 | |
| D6S2749 | 106/194 (55) | 395/624 (63) | 1.37 (1.08–1.72) | .007 | |
| D6S291 | 77/127 (61) | 419/683 (61) | 1.13 (0.87–1.46) | .39 | |
*
Adjusted for patient age, disease severity, use of total body irradiation, use of T-cell depletion, number of mismatches at Msat other than marker of interest and number of HLA-DPB1 disparities.
†
Odds ratio (OR; acute GVHD) and hazard ratio (HR; mortality) measure risks associated with Msat mismatching relative to Msat matching in interest; CI, confidence interval.